Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a strong financial performance with a 45% revenue increase and a reduced net loss. Additionally, there is a strategic expansion of the AUVELITY sales force and ongoing development in multiple therapeutic areas. Although some risks are noted in forward-looking statements, the overall sentiment is positive due to strong revenue growth and effective cost management. The market cap indicates a moderate reaction, likely leading to a stock price increase of 2% to 8%.
Key Financial Performance
Total Revenue $98.7 million, representing a 45% increase year-over-year. This growth was driven by strong sales of Auvelity and Sunosi.
Net Loss $22.3 million, compared to $30.5 million in the prior year. The improvement was due to increased revenue and effective cost management.
Research and Development Expenses $18.2 million, a 10% decrease year-over-year. The reduction was attributed to the completion of certain clinical trials.
Selling, General, and Administrative Expenses $45.6 million, a 15% increase year-over-year. The rise was due to expanded commercial activities and marketing efforts for Auvelity.
Cash and Cash Equivalents $210.4 million, compared to $190.2 million in the prior year. The increase was primarily due to improved cash flow from operations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The discussion includes forward-looking statements regarding financial performance, commercial strategy, and operational plans, which inherently carry risks of inaccuracies or unforeseen challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ami Fadia
Ari Maizel
Axsome Therapeutics
Benjamin Burnett
Blair LLC
Burnett Wells
Co
Division Ami
Division Benjamin
Division Guofang
Division Hoang
Division Jason
Division Lin
Division Madison
Division Marc
EDT Herriot
Fadia Needham
Guofang Li
Herriot Tabuteau
Inc Research
Jason Gerberry
Jefferies LLC
LLC Axsome
LLC Research
Li Wolfe
Lin Tsai
Madison Wynne
Maizel Chief
Marc Goodman
Research Division
Securities LLC
AXSM Transcript
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Positive5-4
The earnings call summary presents a strong financial performance with a 45% revenue increase and a reduced net loss. Additionally, there is a strategic expansion of the AUVELITY sales force and ongoing development in multiple therapeutic areas. Although some risks are noted in forward-looking statements, the overall sentiment is positive due to strong revenue growth and effective cost management. The market cap indicates a moderate reaction, likely leading to a stock price increase of 2% to 8%.
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
Neutral3-13
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call highlights strong prescription growth for key products like AUVELITY and SUNOSI, successful launch of SYMBRAVO, and promising pipeline developments. The Q&A reveals positive analyst sentiment towards growth drivers and market opportunities, despite some unclear management responses. The strategic plan indicates expansion and potential new approvals, suggesting future growth. The market cap of $3.8 billion suggests moderate sensitivity to news. Overall, the combination of strong current performance and optimistic future guidance justifies a positive stock price outlook over the next two weeks.
AXSM Slides
Axsome Q1 2026 slides: 57% revenue growth amid FDA approval milestone2026-05-04
Axsome Q4 2025 slides: revenue surges 66%, stock dips on expenses2026-02-23
Axsome Therapeutics Q3 2025 slides: Strong revenue growth amid pipeline expansion2025-11-03
Axsome Q2 2025 slides: revenue surges 72% YoY, pipeline advances on track2025-08-04
AXSM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
